| Name | Title | Contact Details |
|---|
Fidelis Care is the New York State Catholic Health Plan, providing quality, affordable, New York State-sponsored health insurance coverage for people of all ages and at all stages of life. From its origin in 1993 as the Catholic Health Services Plan of Brooklyn and Queens, Inc., Fidelis Care has grown -- both in the scope of its mission and the services it provides. Today, through a Statewide network of more than 67,000 providers, we support more than one million children and adults, making Fidelis Care one of the largest government programs-based health insurance plans in New York State. Fidelis Care offers free or low-cost comprehensive health insurance, including Medicaid Managed Care, Medicare Advantage, Child Health Plus, and products available through NY State of Health: The Official Health Plan Marketplace. Additionally, Fidelis Care offers Managed Long Term Care products for adults who qualify for nursing home care, but are capable of staying safely in their own homes with the right care and support.
Sturdy Memorial Hospital Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Sturdy Memorial Hospital Inc. is based in Attleboro, MA. You can find more information on Sturdy Memorial Hospital Inc. at www.sturdymemorial.org
BodyMedia is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pittsburgh, PA. To find more information about BodyMedia, please visit www.bodymedia.com
Agel Enterprises is a Lehi, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.